Abstract:Background: Diabetic retinopathy (DR) stands as a prominent complication of diabetes. Berberine (BBR) has reported to be effective to ameliorate the retinal damage of DR. Studying the potential immunological mechanisms of BBR on the streptozotocin (STZ) induced DR mouse model will explain the therapeutic mechanisms of BBR and provide theoretical basis for the clinical application of this drug. Methods: C57BL/6 J mice were induced into a diabetic state using a 50 mg/(kg & sdot;d) dose of STZ over a 5 -day period. Subsequently, they were subjected to a high -fat diet (HFD) for one month. Following a 5 -week treatment with 100 mg/(kg & sdot;d) BBR, the concentrations of inflammatory factors in the mice 's peripheral blood were determined using an enzyme -linked immunosorbent assay (ELISA). Hematoxylin-eosin staining was employed to scrutinize pathological changes in the mice 's retinas, while flow cytometry assessed the proportions of Tlymphocyte subsets and the activation status of dendritic cells (DCs) in the spleen and lymph nodes. CD4 + T cells and DC2.4 cell lines were utilized to investigate the direct and indirect effects of BBR on T cells under high glucose conditions in vitro. Results: Following 5 weeks of BBR treatment in the streptozotocin (STZ) mouse model of DR, we observed alleviation of retinal lesions and a down -regulation in the secretion of inflammatory cytokines, namely TNF- alpha, IL1 beta, and IL -6, in the serum of these mice. And in the spleen and lymph nodes of these mice, BBR inhibited the proportion of Th17 cells and promoted the proportion of Treg cells, thereby down -regulating the Th17/Treg ratio. Additionally, in vitro experiments, BBR directly inhibited the expression of the transcription factor ROR gamma t and promoted the expression of the transcription factor Foxp3 in T cells, resulting in a down -regulation of the Th17/Treg ratio. Furthermore, BBR indirectly modulated the Th17/Treg ratio by suppressing the secretion of TNF- alpha, IL-1 beta, and IL -6 by DCs and enhancing the secretion of indoleamine 2,3-dioxygenase (IDO) and transforming growth factor -beta (TGF- beta) by DCs. This dual action inhibited Th17 cell differentiation while promoting Treg cells. Conclusion: Our findings indicate that BBR regulate T cell subpopulation differentiation, reducing the Th17/Treg ratio by directly or indirectly pathway. This represents a potential therapeutic avenue of BBR for improving diabetic retinopathy.

Berberine attenuates apoptosis in rat retinal Müller cells stimulated with high glucose via enhancing autophagy and the AMPK/mTOR signaling.

Berberine Protects Against Diabetic Retinopathy by Inhibiting Cell Apoptosis Via Deactivation of the NF‑κB Signaling Pathway.

Autophagy protects against senescence and apoptosis via the RAS-mitochondria in high-glucose-induced endothelial cells.

Ghrelin Ameliorates Diabetic Retinal Injury: Potential Therapeutic Avenues for Diabetic Retinopathy

Activation of the GABA-alpha receptor by berberine rescues retinal ganglion cells to attenuate experimental diabetic retinopathy

Protective Mechanism of Berberine on Human Retinal Pigment Epithelial Cells Against Apoptosis Induced by Hydrogen Peroxide Via the Stimulation of Autophagy

Berberine Alleviates the Damage, Oxidative Stress and Mitochondrial Dysfunction of PC12 Cells Induced by High Glucose by Activating the KEAP1/Nrf2/ARE Pathway

HGSD attenuates neuronal apoptosis through enhancing neuronal autophagy in the brain of diabetic mice: the role of AMP-activated protein kinase.

Berberine Protects Human Retinal Pigment Epithelial Cells From Hydrogen Peroxide-Induced Oxidative Damage Through Activation Of Ampk

Berberine Enhances the AMPK Activation and Autophagy and Mitigates High Glucose-Induced Apoptosis of Mouse Podocytes.

Berberine Alleviates Diabetic Retinopathy by Regulating the Th17/Treg Ratio.

Berberine Improves Kidney Function in Diabetic Mice via AMPK Activation

Beneficial Effects of Berberine on Oxidized LDL-Induced Cytotoxicity to Human Retinal Müller Cells

Amorphous Solid Dispersion of Berberine Mitigates Apoptosis Via Ipla2β/cardiolipin/opa1 Pathway in Db/db Mice and in Palmitate-treated MIN6 Β-Cells.

Berberine Inhibits Gluconeogenesis in Spontaneous Diabetic Rats by Regulating the AKT/MAPK/NO/cGMP/PKG Signaling Pathway

Berberine regulates mesangial cell proliferation and cell cycle to attenuate diabetic nephropathy through the PI3K/Akt/AS160/GLUT1 signalling pathway

Berberine Improves Insulin Resistance in Cardiomyocytes Via Activation of 5′-Adenosine Monophosphate-Activated Protein Kinase

Berberine Mitigates High Glucose-Induced Podocyte Apoptosis by Modulating Autophagy Via the Mtor/p70s6k/4ebp1 Pathway.

Berberine Improves Glucose Metabolism in Diabetic Rats by Inhibition of Hepatic Gluconeogenesis.

Berberine Ameliorates High Glucose-Induced Cardiomyocyte Injury via AMPK Signaling Activation to Stimulate Mitochondrial Biogenesis and Restore Autophagic Flux

Berberine Ameliorates Diabetic Cardiomyopathy in Mice by Decreasing Cardiomyocyte Apoptosis and Oxidative Stress